Nadine Tung, MD of Dana Farber/Harvard Cancer Center @DanaFarber @Harvard discusses a phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes presented at this year’s virtual ASCO.
Nadine Tung, MD on A Phase II Study of Olaparib Monotherapy in Breast Cancer #ASCO2020 #ASCO @DanaFarber @Harvard
By Editor